BOSTON, March 21, 2018 /PRNewswire/ -- Juniper
Pharmaceuticals, Inc. (Nasdaq: JNP), a diversified healthcare
company with core businesses of its CRINONE®
(progesterone gel) franchise and fee-for-service pharmaceutical
development and manufacturing business JPS, today
announced the appointment of Richard
Messina to the Company's Board of Directors.
"We welcome Richard to Juniper's Board of Directors. As a
long-term shareholder, Richard's perspective will be a valuable
contribution to our ongoing process of reviewing strategic
alternatives while we continue to drive growth in our core
businesses," said Alicia Secor,
Juniper's President and CEO. "Richard has witnessed Juniper
transform throughout the years, and we look forward to working with
him as we seek to build shareholder value."
Mr. Messina is the Founder, President and Chief Executive
Officer of The Benchmark Company, LLC, an investment banking and
financial advisory firm.
About Juniper Pharmaceuticals
Juniper
Pharmaceuticals, Inc.'s core businesses include its
CRINONE® (progesterone gel) franchise and Juniper Pharma
Services, which provides high-end fee-for-service pharmaceutical
development and clinical trials manufacturing to clients. The
Company is also leveraging its differentiated intravaginal ring
technology, which offers the potential to address unmet needs in
women's health. Please visit www.juniperpharma.com for more
information.
Juniper Pharmaceuticals™ is a trademark of Juniper
Pharmaceuticals, Inc., in the U.S. and EU.
CRINONE® is a registered trademark of Merck KGaA,
Darmstadt, Germany, outside the
U.S. and of Allergan plc in the U.S.
Forward Looking Statements
This press release contains "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995, including statements relating to Juniper's exploration of
strategic alternatives. Management believes that these
forward-looking statements are reasonable as and when made.
However, such forward-looking statements involve known and unknown
risks, uncertainties, and other factors that may cause actual
results to differ materially from those projected in the
forward-looking statements. These risks and uncertainties include,
but are not limited to the uncertainty associated with being able
to identify, evaluate and complete any strategic alternative, the
impact of the announcement of the Company's review of strategic
alternatives, as well as any strategic alternative that may be
pursued, on the Company's business. For a discussion of certain
risks and uncertainties associated with Juniper Pharmaceuticals'
forward-looking statements, please review the Company's reports
filed with the SEC, including, but not limited to, its Annual
Report on Form 10-K for the period ended December 31, 2017 and
subsequent filings with the SEC. Readers are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date on which they are made. These statements are
based on management's current expectations and Juniper
Pharmaceuticals does not undertake any responsibility to revise or
update any forward-looking statements contained herein, except as
expressly required by law.
Investor Contact:
Argot Partners
Laura Perry or Heather Savelle
212-600-1902
laura@argotpartners.com
heather@argotpartners.com
To receive Juniper's press releases, SEC filings or calendar
alerts by email click
here.
Follow us on
LinkedIn
View original content with
multimedia:http://www.prnewswire.com/news-releases/juniper-pharmaceuticals-appoints-richard-messina-to-board-of-directors-300617302.html
SOURCE Juniper Pharmaceuticals, Inc.
